What is Biofrontera?
Biofrontera, established in 1997 and headquartered in Leverkusen, Germany, is a biopharmaceutical company dedicated to the development and commercialization of dermatological drugs and advanced medical cosmetics. The company's focus lies in creating innovative products designed for skin care, protection, and treatment, addressing a range of dermatological needs. Its strategic positioning within the healthcare industry is built upon a foundation of scientific research and product development aimed at improving patient outcomes and enhancing skin health.
How much funding has Biofrontera raised?
Biofrontera has raised a total of $47.9M across 2 funding rounds:
Share Placement
$29.9M
Stock Offering
$18M
Share Placement (2021): $29.9M, investors not publicly disclosed
Stock Issuance/Offering (2021): $18M, investors not publicly disclosed
What's next for Biofrontera?
The recent major strategic investment into Biofrontera, following substantial prior capital raises totaling $47.9M, indicates a strong market confidence and positions the company for accelerated expansion. This infusion of capital is likely to fuel further research and development initiatives, potentially leading to the launch of new therapeutic agents and the broadening of its product portfolio. The company's enterprise-level funding context suggests a focus on scaling operations, enhancing market penetration, and potentially exploring strategic partnerships or acquisitions to solidify its competitive advantage in the global dermatology market.
See full Biofrontera company page
